Featured news from NHIVNA
HIV-related news from NAM
WHO issues new HIV recommendations calling for earlier ARV initiation
Lesley Odendal, 2013-06-30 17:20:00
New HIV treatment guidelines by the World Health Organization (WHO) launched today at the 7th International AIDS Society conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur, recommend offering antiretroviral therapy to all HIV-positive people at CD4 counts below 500 cells/mm3.
According to the WHO, initiation of antiretroviral therapy at a CD4 count below 500 could avert an additional 3 million deaths and prevent 3.5 million more new HIV infections between 2013 and 2025 if the guidance is widely implemented. Although the earlier treatment initiation recommendations follow systematic reviews which show that this is the best threshold at which to initiate ARVs, the vast majority of people initiating ARVs globally are doing so at a CD4 count below 100 cells/mm3.
However, the WHO estimates that as a result of the new guidance 25.9 million people will now be eligible for ARVs. An additional 9.2 million people have become eligible compared to the criteria used in the previous 2010 guidance.
The previous WHO recommendation, set in 2010, was to offer treatment at a CD4 count of 350 or below. Ninety per cent of all countries have adopted the 2010 recommendation. A few countries, such as Algeria, Argentina and Brazil, are already offering treatment at 500 cells/mm3.
Evidence from the HTPN 052 study found that initiating ARVs at CD4 counts between 250 and 500 reduced the risk of HIV transmission in heterosexual serodiscordant couples by 96%. There is also evidence that earlier treatment will help people with HIV to live longer, healthier lives.
Other key new recommendations include the use of viral load testing as the preferred approach to monitoring the success of ART and diagnosing treatment failure, in addition to clinical and CD4 monitoring of people receiving ART (as opposed to CD4 testing) and community-based HIV testing and counselling and HIV testing of adolescents to diagnose people with HIV earlier and link them to care and treatment.
“There’s no greater motivating factor for people to stick to their HIV treatment than knowing the virus is ‘undetectable’ in their blood,” said Dr Gilles van Cutsem, Médecins Sans Frontières/Doctors Without Borders (MSF)’s Medical Co-ordinator in South Africa.
“Viral load testing is the optimal way of maintaining people on first-line treatment and knowing when to switch them to second-line drugs, so it’s high time it’s made available in countries with a heavy burden of disease,” he went on. “With these new guidelines our collective goal should now be to scale up without messing up: to reach more people, retain them on treatment, and with an undetectable viral load.”
The new guidelines also recommend antiretroviral therapy to all children with HIV under 5 years of age and to all children over the age of five with a CD4 cell count below 500.
Women with HIV who are pregnant or breastfeeding are recommended to start treatment irrespective of CD4 cell count. Although the guidelines state that women may discontinue treatment after breastfeeding has ceased if they are not eligible for treatment, WHO also recommends that because it is simpler to manage, all women should stay on treatment once they have started.
The new guidelines also recommend antiretroviral therapy for all people living with HIV who are part of a serodiscordant couple (this refers to two people in a sexual relationship where one partner has HIV and the other does not, sometimes also called 'mixed status').
WHO continues to recommend that all people with HIV with active tuberculosis (TB) or with hepatitis B receive antiretroviral therapy. The new guidelines also support the active acceleration of the phasing out of d4T (stavudine, Zerit) in first-line ART regimens for adults and adolescents.
The Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommend that all adults should be offered tenofovir (TDF, Viread), 3TC (lamivudine, Epivir) or FTC (emtricitabine, Emtriva) and efavirenz (Sustiva or Stocrin), preferably in a fixed-dose combination. This combination is easier to take and safer than alternative combinations previously recommended and can be used in adults, pregnant women, adolescents and older children.
The recommendation to provide efavirenz to pregnant women follows a systematic review which found no increased risk of overall birth defects among women exposed to efavirenz during the first trimester of pregnancy compared with exposure to other antiretroviral drugs. Prevalence of overall birth defects with first trimester efavirenz exposure was similar to the ranges reported in the general population.
However, healthcare workers and people with HIV at the conference found this recommendation problematic as the package insert of efavirenz still states that it should not be used in pregnant women during the first trimester, resulting in some pregnant women not adhering to their treatment. “We need the WHO to address this before they make recommendations such as these,” said one conference delegate.
The consolidated guidelines also recommend the implementation of community-based HIV counselling and testing (HCT) in generalised epidemics, especially for those most at risk of HIV such as men who have sex with men (MSM), people who inject drugs (PWID), migrants and sex workers. WHO also recommended the minimisation of out-of-pocket payments for health care, peer support for patients, the use of mobile phone text messages to promote adherence and retention in care and nutritional support in places where there is food insecurity.
Source:1
